Journal article

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Eva M Lonn, Jackie Bosch, Patricio Lopez-Jaramillo, Jun Zhu, Lisheng Liu, Prem Pais, Rafael Diaz, Denis Xavier, Karen Sliwa, Antonio Dans, Alvaro Avezum, Leopoldo S Piegas, Katalin Keltai, Matyas Keltai, Irina Chazova, Ron JG Peters, Claes Held, Khalid Yusoff, Basil S Lewis, Petr Jansky Show all

NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2016

Abstract

BACKGROUND: Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its role in persons at intermediate risk and with lower blood pressure is unclear. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to receive either candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke; the second coprimary ..

View full abstract

University of Melbourne Researchers